Medtronic Completes Acquisition of CathWorks to Enhance Cardiovascular Care

Medtronic has finalized its acquisition of CathWorks, a company specializing in innovative cardiac technologies. This acquisition follows a successful partnership and aims to enhance the diagnosis and treatment of coronary artery disease using the drug-free, wire-free FFRangio® System. The acquisition is valued at $585 million and is expected to strengthen Medtronic’s portfolio in interventional cardiology, providing physicians with advanced data-driven insights.